PARP inhibitors: what we know and what we have yet to know.
Puhalla
Shannon
S
University of Pittsburgh, Cancer Institute, Division of Hematology/Oncology, Magee Womens Hospital, Pittsburgh, Pennsylvania, USA.
D019313:BRCA1 Protein / Q000235:genetics / Q000378:metabolism; D024682:BRCA2 Protein / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D011065:Poly(ADP-ribose) Polymerases / Q000502:physiology*
D019313:BRCA1 Protein; D024682:BRCA2 Protein; D004791:Enzyme Inhibitors; D011065:Poly(ADP-ribose) Polymerases